Setting a new standard for the treatment of chronic inflammation. Press Releases Catch up on the latest news from Evommune. September 9, 2021 Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline January 7, 2021 Evommune In-Licenses Three Development Programs Focused on Treating Inflammatory Conditions from Dermira, a Wholly-Owned Subsidiary of Eli Lilly and Company January 5, 2021 Evommune to Present at 2021 Virtual Dermatology Summit November 18, 2020 Evommune, Inc. Raises $12.5M in Seed Funding to Accelerate the Development of Transformative Medicines for Chronic Inflammatory Diseases 12 We have a range of chronic inflammatory disease programs currently in development. See Our Pipeline